ARS Pharmaceuticals (SPRY)

• Market cap: $1.22B
• 1 day: 1.71%
• 5 days: -14.95%
• 1 month: 13.00%
• 3 months: -17.63%
• 6 months: 34.33%
• Year to date: 16.90%
• 1 year: 96.55%
• 5 years: 106.60%
• 10 years: 106.60%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Employees: 24

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

308% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 12

148% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 23

74% more capital invested

Capital invested by funds: $534M [Q2] → $929M (+$395M) [Q3]

50% more call options, than puts

Call options by funds: $14.2M | Put options by funds: $9.47M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

32% more funds holding

Funds holding: 114 [Q2] → 150 (+36) [Q3]

1.39% more ownership

Funds ownership: 64.72% [Q2] → 66.11% (+1.39%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $27 116% upside
• Avg. target: $28 120% upside
• High target: $28 124% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Raymond James Ryan Deschner 86% 1-year accuracy 6 / 7 met price target	124% upside $28	Strong Buy Maintained	14 Jan 2025
Leerink Partners Roanna Ruiz 25% 1-year accuracy 2 / 8 met price target	116% upside $27	Outperform Maintained	13 Jan 2025